Aberdeen Group plc Takes Position in InspireMD, Inc. $NSPR

Aberdeen Group plc bought a new stake in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,481,117 shares of the company’s stock, valued at approximately $5,979,000. Aberdeen Group plc owned approximately 0.06% of InspireMD at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Creative Planning bought a new stake in InspireMD in the 2nd quarter valued at $44,000. Raymond James Financial Inc. boosted its position in shares of InspireMD by 28.9% during the 2nd quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after acquiring an additional 10,000 shares in the last quarter. Rosalind Advisors Inc. boosted its position in shares of InspireMD by 0.6% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock valued at $5,196,000 after acquiring an additional 14,109 shares in the last quarter. Soleus Capital Management L.P. increased its stake in InspireMD by 99.5% in the second quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock valued at $4,282,000 after acquiring an additional 940,831 shares during the period. Finally, Affiance Financial LLC raised its position in InspireMD by 32.4% in the third quarter. Affiance Financial LLC now owns 250,370 shares of the company’s stock worth $603,000 after purchasing an additional 61,248 shares in the last quarter. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Stock Up 4.0%

Shares of NSPR stock opened at $1.81 on Friday. The company has a market capitalization of $76.69 million, a P/E ratio of -2.41 and a beta of 0.93. InspireMD, Inc. has a 12-month low of $1.51 and a 12-month high of $3.80. The firm has a 50-day moving average price of $1.77 and a 200 day moving average price of $2.08.

Wall Street Analysts Forecast Growth

Separately, Maxim Group initiated coverage on shares of InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $5.00.

Insider Activity at InspireMD

In other news, insider Shane Thomas Gleason sold 17,593 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $1.62, for a total value of $28,500.66. Following the transaction, the insider directly owned 1,174,664 shares of the company’s stock, valued at $1,902,955.68. The trade was a 1.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 61,194 shares of company stock valued at $99,188. 34.06% of the stock is owned by insiders.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.